What is the share price of Procter & Gamble Health Ltd (PGHL) today?
The share price of PGHL as on 10th July 2025 is ₹5677.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Procter & Gamble Health Ltd (PGHL) share?
The past returns of Procter & Gamble Health Ltd (PGHL) share are- Past 1 week: -2.84%
- Past 1 month: -0.24%
- Past 3 months: 8.74%
- Past 6 months: 7.97%
- Past 1 year: 9.67%
- Past 3 years: 32.87%
- Past 5 years: 36.53%
What are the peers or stocks similar to Procter & Gamble Health Ltd (PGHL)?
The peers or stocks similar to Procter & Gamble Health Ltd (PGHL) include:What is the dividend yield % of Procter & Gamble Health Ltd (PGHL) share?
The current dividend yield of Procter & Gamble Health Ltd (PGHL) is 4.58.What is the market cap of Procter & Gamble Health Ltd (PGHL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Procter & Gamble Health Ltd (PGHL) is ₹9424.30 Cr as of 10th July 2025.What is the 52 week high and low of Procter & Gamble Health Ltd (PGHL) share?
The 52-week high of Procter & Gamble Health Ltd (PGHL) is ₹6175.50 and the 52-week low is ₹4863.What is the PE and PB ratio of Procter & Gamble Health Ltd (PGHL) stock?
The P/E (price-to-earnings) ratio of Procter & Gamble Health Ltd (PGHL) is 46.89. The P/B (price-to-book) ratio is 17.51.Which sector does Procter & Gamble Health Ltd (PGHL) belong to?
Procter & Gamble Health Ltd (PGHL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Procter & Gamble Health Ltd (PGHL) shares?
You can directly buy Procter & Gamble Health Ltd (PGHL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Procter & Gamble Health Ltd
PGHL Share Price
5,677.500.27% (-15.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
PGHL Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PGHL Performance & Key Metrics
PGHL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 37.52 | 17.51 | 4.58% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.59 | 6.40 | 0.79% |
PGHL Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
PGHL Company Profile
Procter & Gamble Health Limited, formerly Merck Limited, is engaged in manufacturing and marketing of pharmaceuticals, bulk drugs, fine chemicals and pigments
SUNPHARMA
PE Ratio
36.50
36.50
1Y Return
4.00%
4.00%
Buy Reco %
87.10
87.10
CIPLA
PE Ratio
22.64
22.64
1Y Return
2.34%
2.34%
Buy Reco %
73.33
73.33
TORNTPHARM
PE Ratio
59.13
59.13
1Y Return
13.13%
13.13%
Buy Reco %
70.83
70.83
DRREDDY
PE Ratio
18.58
18.58
1Y Return
4.24%
4.24%
Buy Reco %
51.72
51.72
MANKIND
PE Ratio
52.73
52.73
1Y Return
18.31%
18.31%
Buy Reco %
81.25
81.25
PGHL Sentiment Analysis
PGHL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
PGHL Stock Summary · June 2025
The company demonstrated robust fiscal performance for the nine-month period ending March 31, 2025, with an 8% sales increase and a remarkable 27% rise in profit after tax, underscoring the effectiveness of its integrated growth strategy. Despite navigating a challenging macroeconomic landscape, management remains committed to enhancing product superiority and expanding market share, particularly through innovative e-commerce initiatives and a new distribution model aimed at rural outreach. The emphasis on consumer health, particularly addressing Vitamin B deficiency, has fostered positive market sentiment, bolstered by educational campaigns that raise awareness of product benefits. Continuous engagement with healthcare professionals and consumer feedback integration are pivotal in driving innovation and maintaining brand loyalty, positioning the company for sustained growth and operational excellence.
PGHL Stock Growth Drivers
PGHL Stock Growth Drivers
6Strong Financial Performance
The company has reported significant financial achievements, including an 8% increase in sales to Rs.
Effective Integrated Growth Strategy
The company's Integrated Growth Strategy has been pivotal in driving growth and profitability. It focuses
PGHL Stock Challenges
PGHL Stock Challenges
0
Hmm, looks like there are nochallenges
PGHL Forecast
PGHL Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
PGHL
PGHL
Income
Balance Sheet
Cash Flow
Annual Normal View
PGHL Income Statement
PGHL Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,424.75 | 1,026.83 | 1,127.60 | 1,248.01 | 1,166.89 | 1,230.53 | ||||||
Raw Materials | 444.47 | 310.39 | 344.55 | 358.99 | 329.69 | 871.60 | ||||||
| Power & Fuel Cost | 19.09 | 12.97 | 14.70 | 12.88 | 8.50 | |||||||
| Employee Cost | 182.93 | 153.66 | 167.56 | 206.17 | 215.16 | |||||||
| Selling & Administrative Expenses | 257.28 | 173.99 | 203.91 | 196.86 | 181.66 | |||||||
| Operating & Other expenses | 136.68 | 111.70 | 116.01 | 130.04 | 130.44 | |||||||
EBITDA | 384.30 | 264.12 | 280.87 | 343.07 | 301.44 | 358.93 | ||||||
| Depreciation/Amortization | 29.45 | 30.04 | 27.08 | 28.10 | 27.40 | 23.85 | ||||||
| PBIT | 354.85 | 234.08 | 253.79 | 314.97 | 274.04 | 335.08 | ||||||
| Interest & Other Items | 0.00 | 0.80 | 0.42 | 0.77 | 0.72 | 0.63 | ||||||
| PBT | 354.85 | 233.28 | 253.37 | 314.20 | 273.32 | 334.45 | ||||||
| Taxes & Other Items | 100.77 | 56.48 | 60.85 | 84.73 | 72.34 | 83.26 | ||||||
| Net Income | 254.08 | 176.80 | 192.52 | 229.47 | 200.98 | 251.19 | ||||||
| EPS | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 151.32 | ||||||
| DPS | 230.00 | 130.00 | 52.50 | 95.00 | 260.00 | 140.00 | ||||||
| Payout ratio | 1.50 | 1.22 | 0.45 | 0.69 | 2.15 | 0.93 |
PGHL Company Updates
FY 2025FY 2025
Investor Presentation
Jun 16PDF
FY 2019FY 2019
PGHL Stock Peers
PGHL Past Performance & Peer Comparison
PGHL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Procter & Gamble Health Ltd | 46.89 | 17.51 | 4.58% |
| Sun Pharmaceutical Industries Ltd | 36.50 | 5.50 | 0.96% |
| Cipla Ltd | 22.64 | 3.82 | 1.08% |
| Torrent Pharmaceuticals Ltd | 59.13 | 14.89 | 0.18% |
PGHL Stock Price Comparison
Compare PGHL with any stock or ETFCompare PGHL with any stock or ETF
PGHL
PGHL Holdings
PGHL Shareholdings
PGHL Promoter Holdings Trend
PGHL Promoter Holdings Trend
PGHL Institutional Holdings Trend
PGHL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
PGHL Shareholding Pattern
PGHL Shareholding Pattern
PGHL Shareholding History
PGHL Shareholding History
Foreign Institutions
Mutual Funds Invested in PGHL
Mutual Funds Invested in PGHL
No mutual funds holding trends are available
Top 5 Mutual Funds holding Procter & Gamble Health Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 4.3102% | Percentage of the fund’s portfolio invested in the stock 0.61% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 118/248 (-8) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.1945% | Percentage of the fund’s portfolio invested in the stock 2.42% | Change in the portfolio weight of the stock over the last 3 months -0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 7/132 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.4990% | Percentage of the fund’s portfolio invested in the stock 4.94% | Change in the portfolio weight of the stock over the last 3 months 0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 3/56 (+1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing PGHL stock
smallcases containing PGHL stock
Looks like this stock is not in any smallcase yet.
PGHL Events
PGHL Events
PGHL Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 4.58%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹45.79 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
PGHL Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 4.58%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹45.79 every year
PGHL Upcoming Dividends
PGHL Upcoming Dividends
No upcoming dividends are available
PGHL Past Dividends
PGHL Past Dividends
Cash Dividend
Ex DateEx DateFeb 21, 2025
Interim
Interim | Div/Share: ₹80.00
Dividend/Share
₹80.00
Ex DateEx Date
Feb 21, 2025
Cash Dividend
Ex DateEx DateNov 28, 2024
Final
Final | Div/Share: ₹60.00
Dividend/Share
₹60.00
Ex DateEx Date
Nov 28, 2024
Cash Dividend
Ex DateEx DateFeb 14, 2024
Interim
Interim | Div/Share: ₹50.00
Dividend/Share
₹50.00
Ex DateEx Date
Feb 14, 2024
Cash Dividend
Ex DateEx DateFeb 14, 2024
Special
Special | Div/Share: ₹150.00
Dividend/Share
₹150.00
Ex DateEx Date
Feb 14, 2024
Cash Dividend
Ex DateEx DateNov 23, 2023
Final
Final | Div/Share: ₹50.00
Dividend/Share
₹50.00
Ex DateEx Date
Nov 23, 2023
PGHL Stock News & Opinions
PGHL Stock News & Opinions
Articles & Videos
Corporate
Procter & Gamble Health to conduct board meeting
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Board of Procter & Gamble Health recommends final dividend
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 45 per equity Share (i.e. 450%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 31.40% in the March 2025 quarter
Net profit of Procter & Gamble Health rose 31.40% to Rs 61.18 crore in the quarter ended March 2025 as against Rs 46.56 crore during the previous quarter ended March 2024. Sales rose 23.17% to Rs 310.99 crore in the quarter ended March 2025 as against Rs 252.48 crore during the previous quarter ended March 2024. ParticularsQuarter EndedMar. 2025Mar. 2024% Var. Sales310.99252.48 23 OPM %26.0226.71 - PBDT83.9069.56 21 PBT78.5362.72 25 NP61.1846.56 31 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Procter & Gamble Health declare Quarterly Result
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 26.13% in the December 2024 quarter
Net profit of Procter & Gamble Health rose 26.13% to Rs 90.90 crore in the quarter ended December 2024 as against Rs 72.07 crore during the previous quarter ended December 2023. Sales declined 0.06% to Rs 309.77 crore in the quarter ended December 2024 as against Rs 309.97 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales309.77309.97 0 OPM %39.8532.79 - PBDT127.24106.64 19 PBT121.6999.72 22 NP90.9072.07 26 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Board of Procter & Gamble Health recommends interim dividend
Procter & Gamble Health announced that the Board of Directors of the Company at its meeting held on 12 February 2025, inter alia, have recommended the interim dividend of Rs 80 per equity Share (i.e. 800%) , subject to the approval of the shareholders.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
P&G Health gains as Q3 PAT jumps 26% YoY to Rs 91 cr; declares interim dividend of Rs 80/share
The company's revenue from operations remained flat to Rs 309.77 crore in Q3 FY25, compared to the same quarter of the previous year. Total expenses were at Rs 192.04 crore in Q2 December 2024, down 10.85% on a YoY basis. The cost of materials consumed stood at Rs 61.60 crore (down 10.85% YoY), while employee benefits expenses came in at Rs 61.60 crore (down 13.04% YoY) during the period under review. Milind Thatte, Managing Director, P&G Health India, said, 'This quarter was a period of strategic reinforcement as we took proactive steps to strengthen our supply network. We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organizational structure. We are confident that this strategy will enable us to meet the evolving needs of our consumers and healthcare professionals alike.' Meanwhile, the board has declared an interim dividend of Rs 80 per equity share for the financial year 2024-25. The record date for the dividend will be 21 February 2025. Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion. Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Procter & Gamble Health announces board meeting date
Procter & Gamble Health will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
P&G Health hits 52 week high as Q2 PAT jumps 26% YoY to Rs 82 cr
Profit before tax in Q2 FY25 stood at Rs 111.4 crore, up 26.51% as against Rs 88.05 crore posted in same quarter last year. Total expenses were at Rs 205.29 crore in Q2 September 2024, down 7.91% on YoY basis. Cost of materials consumed stood at Rs 48.17 crore (down 44.82% YoY) while employee benefits expenses came in at Rs 46.22 crore (down 23.77% YoY) during the period under review. Milind Thatte, Managing Director, P superiority (across product, package, brand communication, retail execution, and value), constructive disruption and an agile accountable organization'. He further added, 'We are dedicated to enhancing consumer awareness programs and strengthening our relationships with our customers and stakeholders. We continue to invest in initiatives that address the evolving needs of both consumers and healthcare professionals, along with strengthening our go-to-market model. We have also strengthened our reach, distribution, and retail execution, positioning us for long-term competitiveness'. Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. The counter has hit a 52-week high at Rs 5,730.75 in today's intra-day session.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Procter & Gamble Health standalone net profit rises 25.56% in the September 2024 quarter
Net profit of Procter & Gamble Health rose 25.56% to Rs 82.33 crore in the quarter ended September 2024 as against Rs 65.57 crore during the previous quarter ended September 2023. Sales rose 2.78% to Rs 313.41 crore in the quarter ended September 2024 as against Rs 304.93 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales313.41304.93 3 OPM %36.3929.08 - PBDT117.1794.53 24 PBT111.4088.05 27 NP82.3365.57 26 Powered by Capital Market - Live
8 months agoCapital Market - Live
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant